R03AK04 • ipratropium bromide + salbutamol • Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
The combination of ipratropium bromide and salbutamol is used for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma. Ipratropium bromide works by blocking muscarinic receptors, while salbutamol stimulates beta-2 adrenergic receptors, relaxing airway muscles.
The medication is administered as an aerosol or nebulizer solution, as directed by a doctor. It is important to follow the recommended dose to achieve the best results.
Side effects may include dry mouth, cough, tremors, or palpitations. In rare cases, severe allergic reactions or breathing difficulties may occur.
This combination is not recommended for patients with hypersensitivity to any of the components or severe cardiac conditions.
Substance: ipratropium bromide + salbutamol
Date of last drug list: 01-07-2013
Commercial code: W56438001
Concentration: 0.5mg / 2.5mg / 2.5ml
Pharmaceutical form: inhalation solution by nebulization
Quantity: 5
Product type: generic
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.